Skip to main content
Figure 6 | Journal of Translational Medicine

Figure 6

From: Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Figure 6

The combination of cabozantinib and immunotherapy significantly reduced tumor growth in a T cell-dependent manner. (A) Schema of combination therapy study (n =10/group). Tumor growth in mice treated with (B) control, (C) vaccine, (D) cabozantinib, and (E) combination therapy, including the number of tumor-free mice at day 35. (F) To determine the role of T cells in the efficacy of combination therapy, we measured tumor growth in control mice with no depletion (open circles), mice receiving combination therapy with no depletion (closed circles), and mice receiving combination therapy in the absence of CD4+ T cells (open squares) or CD8+ T cells (open triangles) (n =8). Depletion antibodies were administered on days 1-3, 10, 17, 24, and 31 (arrows). Tumor dimensions were measured weekly. Error bars indicate mean ± SEM. Statistical analyses were done by Student's t test. * = P <0.0001 relative to control.

Back to article page